
Ekaterina Poliakova-georgan
Examiner (ID: 12423)
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1637, 1635, 1674 |
| Total Applications | 898 |
| Issued Applications | 492 |
| Pending Applications | 151 |
| Abandoned Applications | 285 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18536006
[patent_doc_number] => 20230241093
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => TARGETING ADISPSIN FOR NONALCOHOLIC STEATOHEPATITIS (NASH)- INDUCED LIVER FIBROSIS
[patent_app_type] => utility
[patent_app_number] => 18/154728
[patent_app_country] => US
[patent_app_date] => 2023-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9490
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18154728
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/154728 | TARGETING ADISPSIN FOR NONALCOHOLIC STEATOHEPATITIS (NASH)- INDUCED LIVER FIBROSIS | Jan 12, 2023 | Pending |
Array
(
[id] => 18567418
[patent_doc_number] => 20230257750
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => SIRNA OF ANGPTL3 AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/092202
[patent_app_country] => US
[patent_app_date] => 2022-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9835
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18092202
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/092202 | SIRNA OF ANGPTL3 AND USE THEREOF | Dec 29, 2022 | Pending |
Array
(
[id] => 18656263
[patent_doc_number] => 20230302157
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => Adeno-Associated Virus Vector Delivery of Muscle Specific Micro-Dystrophin to Treat Muscular Dystrophy
[patent_app_type] => utility
[patent_app_number] => 18/146840
[patent_app_country] => US
[patent_app_date] => 2022-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13216
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18146840
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/146840 | Adeno-Associated Virus Vector Delivery of Muscle Specific Micro-Dystrophin to Treat Muscular Dystrophy | Dec 26, 2022 | Pending |
Array
(
[id] => 18709537
[patent_doc_number] => 20230332156
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
[patent_app_type] => utility
[patent_app_number] => 18/085222
[patent_app_country] => US
[patent_app_date] => 2022-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36271
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18085222
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/085222 | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) | Dec 19, 2022 | Issued |
Array
(
[id] => 18469210
[patent_doc_number] => 20230203494
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 18/067363
[patent_app_country] => US
[patent_app_date] => 2022-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17645
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18067363
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/067363 | AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAME | Dec 15, 2022 | Abandoned |
Array
(
[id] => 19051232
[patent_doc_number] => 20240093201
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/061371
[patent_app_country] => US
[patent_app_date] => 2022-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67371
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18061371
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/061371 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | Dec 1, 2022 | Pending |
Array
(
[id] => 18552426
[patent_doc_number] => 20230250435
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => PCSK9 TARGETING OLIGONUCLEOTIDES FOR TREATING HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 18/060406
[patent_app_country] => US
[patent_app_date] => 2022-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22657
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060406
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/060406 | PCSK9 TARGETING OLIGONUCLEOTIDES FOR TREATING HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS | Nov 29, 2022 | Abandoned |
Array
(
[id] => 20108490
[patent_doc_number] => 12359199
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-15
[patent_title] => Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymes
[patent_app_type] => utility
[patent_app_number] => 18/059606
[patent_app_country] => US
[patent_app_date] => 2022-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 19
[patent_no_of_words] => 8395
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18059606
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/059606 | Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymes | Nov 28, 2022 | Issued |
Array
(
[id] => 19381271
[patent_doc_number] => 20240271141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF HEPATITIS B VIRUS (HBV)PROTEIN
[patent_app_type] => utility
[patent_app_number] => 18/558184
[patent_app_country] => US
[patent_app_date] => 2022-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38309
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18558184
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/558184 | COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF HEPATITIS B VIRUS (HBV)PROTEIN | Nov 28, 2022 | Pending |
Array
(
[id] => 20634607
[patent_doc_number] => 12595477
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-07
[patent_title] => Complement Factor B-modulating compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 18/058664
[patent_app_country] => US
[patent_app_date] => 2022-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41017
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 261
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18058664
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/058664 | Complement Factor B-modulating compositions and methods of use thereof | Nov 22, 2022 | Issued |
Array
(
[id] => 19930333
[patent_doc_number] => 12303526
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => DNA compositions and related methods
[patent_app_type] => utility
[patent_app_number] => 18/054813
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 32
[patent_no_of_words] => 26544
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054813
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054813 | DNA compositions and related methods | Nov 10, 2022 | Issued |
Array
(
[id] => 18597603
[patent_doc_number] => 20230272400
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => SYNTHESIS METHOD OF TARGETED DRUG nCoVshRNA 2ACE2
[patent_app_type] => utility
[patent_app_number] => 18/054508
[patent_app_country] => US
[patent_app_date] => 2022-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12742
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054508
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054508 | SYNTHESIS METHOD OF TARGETED DRUG nCoVshRNA 2ACE2 | Nov 9, 2022 | Pending |
Array
(
[id] => 18692991
[patent_doc_number] => 20230323362
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME
[patent_app_type] => utility
[patent_app_number] => 18/054113
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18349
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054113
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054113 | COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME | Nov 8, 2022 | Pending |
Array
(
[id] => 18771160
[patent_doc_number] => 20230365971
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => METHODS AND COMPOSITIONS FOR MACROPHAGE POLARIZATION
[patent_app_type] => utility
[patent_app_number] => 18/052785
[patent_app_country] => US
[patent_app_date] => 2022-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37235
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052785
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052785 | Methods and compositions for macrophage polarization | Nov 3, 2022 | Issued |
Array
(
[id] => 18485250
[patent_doc_number] => 20230212583
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => ANTISENSE THERAPEUTICS FOR THE TREATMENT OF CORONAVIRUS
[patent_app_type] => utility
[patent_app_number] => 18/046235
[patent_app_country] => US
[patent_app_date] => 2022-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7227
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046235
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/046235 | ANTISENSE THERAPEUTICS FOR THE TREATMENT OF CORONAVIRUS | Oct 12, 2022 | Pending |
Array
(
[id] => 20535797
[patent_doc_number] => 12552862
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-02-17
[patent_title] => Oligonucleotides for reduction of PD-L1 expression
[patent_app_type] => utility
[patent_app_number] => 18/045109
[patent_app_country] => US
[patent_app_date] => 2022-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 13
[patent_no_of_words] => 45304
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045109
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/045109 | Oligonucleotides for reduction of PD-L1 expression | Oct 6, 2022 | Issued |
Array
(
[id] => 18240935
[patent_doc_number] => 20230073246
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE
[patent_app_type] => utility
[patent_app_number] => 17/938209
[patent_app_country] => US
[patent_app_date] => 2022-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25425
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938209
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/938209 | BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE | Oct 4, 2022 | Pending |
Array
(
[id] => 19083130
[patent_doc_number] => 20240109931
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-04
[patent_title] => OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/960090
[patent_app_country] => US
[patent_app_date] => 2022-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 192113
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17960090
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/960090 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Oct 3, 2022 | Abandoned |
Array
(
[id] => 18389841
[patent_doc_number] => 20230158059
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/937344
[patent_app_country] => US
[patent_app_date] => 2022-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37299
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937344
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/937344 | Prekallikrein-modulating compositions and methods of use thereof | Sep 29, 2022 | Issued |
Array
(
[id] => 18224928
[patent_doc_number] => 20230063922
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => RIBONUCLEOPROTEINS FOR RNA THERAPEUTICS DELIVERY AND GENE SILENCING
[patent_app_type] => utility
[patent_app_number] => 17/930088
[patent_app_country] => US
[patent_app_date] => 2022-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11649
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 182
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930088
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930088 | RIBONUCLEOPROTEINS FOR RNA THERAPEUTICS DELIVERY AND GENE SILENCING | Sep 6, 2022 | Pending |